Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study

References

• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–41
   PubMed Web of Science ®Google Scholar
• Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology (Basel). 2006;212:327–37
   PubMed Web of Science ®Google Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–24
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–73
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker JH. Psoriasis. N Engl J Med. 2009;361:496–509
   PubMed Web of Science ®Google Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79–88
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147–51
   PubMed Web of Science ®Google Scholar
• Amstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology (Basel). 2012;225:121–6
   PubMed Web of Science ®Google Scholar
• de Korte J, Sprangers MAG, Mombers FMC, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140–7
   PubMed Web of Science ®Google Scholar
• Evers AW, Lu Y, Duller P, et al. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–81
   PubMed Web of Science ®Google Scholar
• Colombo GL, Altomare GF, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manage. 2008;4:559–68
   PubMedGoogle Scholar
• Sohn S, Schoffsky O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost of illness study. Dermatology (Basel). 2006;212:137–44
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651–8
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861–7
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:5–70
   Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304:87–113
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10
   PubMed Web of Science ®Google Scholar
• National Clinical Guidance Centre. Psoriasis – Assessment and management of psoriasis. Clinical Guideline. Methods, evidence and recommendations. October 2012. Available from: https://www.nice.org.uk/guidance/cg153/resources/cg153-psoriasis-full-guideline3. Accessed August 20, 2015
   Google Scholar
• Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol. 2008;22:1337–42
   PubMed Web of Science ®Google Scholar
• Paul A, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2011;25:2–11
   PubMed Web of Science ®Google Scholar
• Il trattamento della psoriasi nell’adulto. Sistema Nazionale Linee Guida – Istituto Superiore di Sanità, Associazione Dermatologi Ospedalieri Italiani. Maggio 2013. Available from: http://www.snlg-iss.it/cms/files/LG_psoriasi_rev_aperta.pdf. Accessed August 20, 2015
   Google Scholar
• Questionario Sullo Stato di Salute SF-36 (V1). Available from: http://crc.marionegri.it/sf36/sf36v1ita.htm. Accessed August 20, 2015
   Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983–94
   PubMed Web of Science ®Google Scholar
• Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporine in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25:19–27
   PubMed Web of Science ®Google Scholar
• Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013;2013:805705
   PubMed Web of Science ®Google Scholar
• Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat. 2005;16:37–42
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9
   PubMed Web of Science ®Google Scholar
• Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52:434–44
   PubMed Web of Science ®Google Scholar
• Abuabara K, Wan J, Troxel AB, et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate-to-severe psoriasis. J Am Acad Dermatol. 2013;68:262–9
   PubMed Web of Science ®Google Scholar
• Duffin CK, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170:672–80
   PubMed Web of Science ®Google Scholar
• van Cranenburgh OD, de Korte J, Sprangers MAG, et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169:398–405
   PubMed Web of Science ®Google Scholar
• Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5:209–18
   PubMedGoogle Scholar
• O’Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72:589–98
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264–72
   PubMed Web of Science ®Google Scholar